The increase will be paid by transferring SAR 150 million from the retained earnings account to the company's capital, consequently increasing the company's outstanding shares from 20 million to 35 million shares.
The mechanics here deserve careful attention. A bonus share issue funded from retained earnings is not a dilutive capital raise in the traditional sense. It does not bring in new cash. What it does is convert accumulated profits into permanent capital, which signals that management believes the earnings base is durable enough to lock in at the balance sheet level. It also increases share count and, by extension, liquidity on the exchange, which matters for a company that listed on the main market of Tadawul only in early 2024.
The deeper question for sector analysts is what Avalon's move reveals about the trajectory of domestic pharmaceutical manufacturing in Saudi Arabia.
The company develops, manufactures, markets, and distributes a range of pharmaceutical and generic medicines in Saudi Arabia and abroad through a diverse, high-quality product portfolio.
Saudi Arabia's Vision 2030 healthcare privatization agenda has consistently emphasized domestic pharmaceutical production as a strategic priority, reducing import dependency and building local manufacturing capacity. A company that is generating sufficient retained earnings to fund a 75% capital expansion from its own balance sheet is, in operational terms, demonstrating that domestic pharmaceutical manufacturing can be commercially viable at scale. That is a meaningful data point for any investor evaluating the sector's long-term earnings power.
The Bahrain picture is more cautionary.
The Bahrain Bourse All Share Index snapped a three-month winning streak in July 2026, dropping 4.2 per cent to close the month at 1,956.33 points, driven down by broad weakness across key sectors.
According to a report by Kamco Invest, the pullback was widespread, with six out of seven sector indices trading lower. Heavyweight sectors bore the brunt of the downturn, led by materials, which registered the sharpest drop of 6.6 per cent. The financial sector slipped 4.1 per cent, while real estate declined 2.6 per cent.
The breadth of the decline is the critical detail. When a small, less liquid market falls across nearly every sector simultaneously, the cause is rarely idiosyncratic. It reflects either a regional sentiment shift or a macro repricing of risk.
The regional context confirms the latter.
GCC equity markets fell for a third consecutive month in July, dragged down by broad losses across the region, with Saudi Arabia leading the downturn as weakness in key sectors outweighed gains in heavyweights. The MSCI GCC index dropped 0.7 per cent during the month, reflecting low to mid-single-digit declines across most regional exchanges.
Saudi Arabia's benchmark TASI index fell nearly 2 per cent, marking its fourth straight monthly loss.
Against that backdrop, a fall in crude oil prices by more than 20 per cent during the month affected energy names in the region.
For Gulf bourses where energy sector weight is structurally significant, an oil price decline of that magnitude creates an index-level headwind that sector-specific strength in healthcare or insurance can only partially offset.
Key considerations for analysis: the GCC healthcare and insurance complex is demonstrating a degree of resilience that the broader regional indices are not. The structural drivers—mandatory enrollment, Vision 2030 privatization, improving claims infrastructure, and domestic pharmaceutical capacity building—are not cyclical. They are policy-anchored and multi-year in duration. The Bahrain pullback and the broader TASI monthly losses are real, and the oil price compression that underlies them cannot be dismissed. But within that environment, the Sunday session on Tadawul and the Avalon Pharma CMA approval both point in the same direction: capital continues to find its way toward healthcare even when the macro tide is running out.
This article is for informational and analytical purposes only.
